| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Age Differences in Clinical Trial Understanding in Non-Hodgkin Lymphoma Patients
|
Luan, Danny
|
|
|
22 |
7 |
p. e549-e554
|
artikel
|
| 2 |
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies
|
Zeidan, Amer M.
|
|
|
22 |
7 |
p. 523-534
|
artikel
|
| 3 |
Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study
|
Baidoun, Firas
|
|
|
22 |
7 |
p. e485-e494
|
artikel
|
| 4 |
Clinical Characteristics of Posttransplant Lymphoproliferative Disorder After Cord Blood Transplantation Without Antithymocyte Globulin
|
Sumi, Masahiko
|
|
|
22 |
7 |
p. 495-503
|
artikel
|
| 5 |
Clinicopathological Factors Associated with the Prognosis and Chronicity of Lymphomatoid Papulosis: A Retrospective Cohort Study
|
Jung, Joon Min
|
|
|
22 |
7 |
p. e541-e548
|
artikel
|
| 6 |
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B‐Cell Lymphoma: Results from a Phase 1b Study
|
Palomba, M. Lia
|
|
|
22 |
7 |
p. e443-e451
|
artikel
|
| 7 |
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study
|
Palomba, Maria Lia
|
|
|
22 |
7 |
p. 504-512
|
artikel
|
| 8 |
Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms
|
Castillo Tokumori, Franco
|
|
|
22 |
7 |
p. e521-e525
|
artikel
|
| 9 |
Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110]
|
Ghobrial, Irene M.
|
|
|
22 |
7 |
p. 545
|
artikel
|
| 10 |
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study
|
Gerds, Aaron T.
|
|
|
22 |
7 |
p. e532-e540
|
artikel
|
| 11 |
Editorial Board
|
|
|
|
22 |
7 |
p. A1-A2
|
artikel
|
| 12 |
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
|
Schuster, Michael
|
|
|
22 |
7 |
p. 483-494
|
artikel
|
| 13 |
Granulomatous Myositis as a Manifestation of Chronic Graft-Versus-Host Disease: A Case Series and Review of the Literature
|
Roy, Claudie
|
|
|
22 |
7 |
p. e459-e462
|
artikel
|
| 14 |
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable
|
Nooka, AK
|
|
|
22 |
7 |
p. e526-e531
|
artikel
|
| 15 |
Impact of Frailty on Hospital Outcomes Among Patients with Lymphoid Malignancies Receiving Autologous Hematopoietic Stem Cell Transplantation in the United States
|
Rubens, Muni
|
|
|
22 |
7 |
p. e427-e434
|
artikel
|
| 16 |
Impact of Insurance on Overall Survival in Acute Lymphoblastic Leukemia: A SEER Database Study
|
Joshi, Utsav
|
|
|
22 |
7 |
p. e477-e484
|
artikel
|
| 17 |
Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective
|
Moertl, Bernhard
|
|
|
22 |
7 |
p. 474-482
|
artikel
|
| 18 |
Long-Term Clinical Outcomes and Sequelae of Therapy in Early-Stage Orbital Mucosa-Associated Lymphoid Tissue Lymphoma
|
Panda, Goutam
|
|
|
22 |
7 |
p. 513-522
|
artikel
|
| 19 |
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience
|
Hamid, Muhammad Saad
|
|
|
22 |
7 |
p. e435-e442
|
artikel
|
| 20 |
Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021
|
Efficace, Fabio
|
|
|
22 |
7 |
p. 442-459
|
artikel
|
| 21 |
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma
|
Kaddu-Mulindwa, Dominic
|
|
|
22 |
7 |
p. e498-e506
|
artikel
|
| 22 |
Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies
|
Mohan, Meera
|
|
|
22 |
7 |
p. e495-e497
|
artikel
|
| 23 |
SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation
|
Burke, John M.
|
|
|
22 |
7 |
p. 427-435
|
artikel
|
| 24 |
SOHO State of the Art Updates and Next Questions: Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future
|
Luskin, Marlise R.
|
|
|
22 |
7 |
p. 436-441
|
artikel
|
| 25 |
Table of Contents
|
|
|
|
22 |
7 |
p. A3-A5
|
artikel
|
| 26 |
The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis
|
Tremblay, Douglas
|
|
|
22 |
7 |
p. e463-e466
|
artikel
|
| 27 |
The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
|
Gao, Lu
|
|
|
22 |
7 |
p. 535-544
|
artikel
|
| 28 |
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS)
|
Chan, Onyee
|
|
|
22 |
7 |
p. e467-e476
|
artikel
|
| 29 |
Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment
|
Sastow, Dahniel
|
|
|
22 |
7 |
p. e507-e520
|
artikel
|
| 30 |
Thrombotic and Clinical Outcomes in Patients with Hematologic Malignancy and COVID-19
|
Cook, Michael R.
|
|
|
22 |
7 |
p. e452-e458
|
artikel
|
| 31 |
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
|
Dimopoulos, Meletios-Athanasios
|
|
|
22 |
7 |
p. 460-473
|
artikel
|
Tijdschrift beschrijving